Enhancing DNA vaccine efficacy with engineered nanoparticles in cancer immunotherapy

DNA vaccines hold promise for cancer immunotherapy due to their safety and rapid design capabilities. However, their clinical application is hindered by challenges such as low stability, poor cellular uptake, and insufficient immune activation. Recent advancements in nanoparticle technology, particularly calcium phosphate nanoparticles (CP NPs), have shown potential in addressing these issues.This research topic explores the use of engineered nanoparticles, such as ATP-modified and mannose-functionalized CP NPs, to enhance DNA vaccine delivery and efficacy.Key areas of investigation include:- the stabilization of CP NPs- targeted delivery through receptor-mediated uptake- the role of nanoparticles as immunological adjuvantsThis topic invites studies that delve into the physicochemical properties of nanoparticles, their interaction with immune cells, and the resulting immunogenicity in preclinical cancer models. By advancing our understanding of nanoparticle-based delivery systems, this research aims to contribute to the development of more effective cancer vaccines, aligning with the mission of the Cancer Immunity and Immunotherapy section in enhancing immunotherapy strategies.Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.Please note that Dr Wenguang Gu is acting as a part-time CSO of a private company. Topic editors: Wenguang Gu, Yilun Wu Source: https://www.frontiersin.org/research-topics/81165/enhancing-dna-vaccine-efficacy-with-engineered-nanoparticles-in-cancer-immunotherapy